Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 251 to 275 of 326

Guidance programme: Technology appraisal guidance`Remove $Guidance programme: Technology appraisal guidance filter`

Guidance and quality standards awaiting development
Title	Type
Sigvotatug vedotin for Non-small-cell lung cancer [ID6718]	Technology appraisal guidance
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]	Technology appraisal guidance
Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]	Technology appraisal guidance
Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669]	Technology appraisal guidance
Sotagliflozin for treating type 2 diabetes [ID1657]	Technology appraisal guidance
Sotorasib with pemetrexed and carboplatin for untreated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6741]	Technology appraisal guidance
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]	Technology appraisal guidance
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]	Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]	Technology appraisal guidance
Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081	Technology appraisal guidance
Sugemalimab for consolidation treatment of locally advanced or unresectable non-small-cell lung cancer after chemoradiotherapy [ID6737]	Technology appraisal guidance
Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]	Technology appraisal guidance
Surovatamig for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of treatment [ID6631]	Technology appraisal guidance
Surovatamig for treating relapsed or refractory follicular lymphoma after 2 or more treatment lines [TSID12354]	Technology appraisal guidance
Survodutide for managing overweight and obesity [ID6752]	Technology appraisal guidance
Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]	Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]	Technology appraisal guidance
Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]	Technology appraisal guidance
Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]	Technology appraisal guidance
Tarlatamab for maintenance treatment of extensive-stage small-cell lung cancer [ID6749]	Technology appraisal guidance
Tarlatamab for treating limited-stage small-cell lung cancer after chemoradiotherapy [ID6748]	Technology appraisal guidance
Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]	Technology appraisal guidance
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628]	Technology appraisal guidance
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]	Technology appraisal guidance
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]	Technology appraisal guidance

Results per page

10
25
50
All